Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease

JAMA Ophthalmology

Volumn 133, Issue 10, 2015, Pages 1117-1123

  Zhang, Lili ^a   Su, Zhitao ^a   Zhang, Zongduan ^a   Lin, Jing ^a   Li, De Quan ^a   Pflugfelder, Stephen C ^a  

^a CULLEN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; EYE DROPS; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; ANTIINFECTIVE AGENT; CYTOKINE; EYE PROTEIN; TEAR PROTEINS; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; BLEPHARITIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONJUNCTIVA; CONJUNCTIVITIS; CONTROLLED STUDY; ENZYME ACTIVITY; EYELID; GENE EXPRESSION PROFILING; HUMAN; MEIBOMIAN GLAND DYSFUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; COMPLICATION; ENZYMOLOGY; EYELID DISEASE; GENETICS; LACRIMAL FLUID; MEIBOMIAN GLAND; METABOLISM; MIDDLE AGED; PATHOLOGY; TOPICAL DRUG ADMINISTRATION; VERY ELDERLY;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BLEPHARITIS; CASE-CONTROL STUDIES; CONJUNCTIVITIS; CYTOKINES; EYE PROTEINS; EYELID DISEASES; HUMANS; MATRIX METALLOPROTEINASE 9; MEIBOMIAN GLANDS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TEARS; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84943618646     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.2326     Document Type: Article

References (47)

1. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of meibomian gland dysfunction. OptomVis Sci. 1990;67(9):710-712.
2. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7(2) (suppl):S1-S14.
3. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1(3):107-126.
4. Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf. 2014;12(4):273-284.
5. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea. 2007;26(1):42-46.
6. Gilbard JP. Dry eye, blepharitis and chronic eye irritation: divide and conquer. J Ophthalmic Nurs Technol. 1999;18(3):109-115.
7. Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom. 2011;94(2):200-206.
8. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother. 1998;41(suppl B):47-50.
9. Kim HS, Luo L, Pflugfelder SC, Li D-Q. Doxycycline inhibits TGF-beta1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2005;46 (3):840-848.
10. Smith VA, Khan-Lim D, Anderson L, Cook SD, Dick AD. Does orally administered doxycycline reach the tear film? Br J Ophthalmol. 2008;92(6): 856-859.
11. Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2010;51(11):5623-5629.
12. Luo L, Li D-Q, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45 (12):4293-4301.
13. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007; 48(6):2561-2569.
14. Ma P, Bian F, Wang Z, et al. Human corneal epithelium-derived thymic stromal lymphopoietin links the innate and adaptive immune responses via TLRs and Th2 cytokines. Invest Ophthalmol Vis Sci. 2009;50(6):2702-2709.
15. Chotikavanich S, de Paiva CS, Li Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203-3209.
16. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011;52(4):1994-2005.
17. Liu P, Fang AF, LaBadie RR, Crownover PH, Arguedas AG. Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. Antimicrob Agents Chemother. 2011;55(11):5022-5026.
18. Jorgensen DM. Single-dose extended-release oral azithromycin vs 3-day azithromycin for the treatment of group A beta-haemolytic streptococcal pharyngitis/tonsillitis in adults and adolescents: a double-blind, double-dummy study. Clin Microbiol Infect. 2009;15(12):1103-1110.
19. Cohen R. Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. Pediatr Infect Dis J. 2004;23(2) (suppl):S129-S134.
20. Luxameechanporn T, Blair C, Kirtsreesakul V, Thompson K, Naclerio RM. The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice. Int J Infect Dis. 2006;10(5):401-406.
21. Swainston Harrison T, Keam SJ. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs. 2007;67(5):773-792.
22. Kopjar B. Azithromycin is effective in patients with chronic bronchitis. J Antimicrob Chemother. 2002;50(3):433-434.
23. Wang PL. Roles of oral bacteria in cardiovascular diseases: from molecular mechanisms to clinical cases: treatment of periodontal disease regarded as biofilm infection: systemic administration of azithromycin. J Pharmacol Sci. 2010;113(2):126-133.
24. Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis. 2009;48(12):1649-1654.
25. Srivastava P, Bhengraj AR, Jha HC, et al. Differing effects of azithromycin and doxycycline on cytokines in cells from Chlamydia trachomatis-infected women. DNA Cell Biol. 2012;31 (3):392-401.
26. Mishra MK, Kotta K, HaliM, et al. PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine. 2011;7(6):935-944.
27. Bremond-Gignac D, Mariani-Kurkdjian P, Beresniak A, et al. Efficacy and safety of azithromycin 1.5%eye drops for purulent bacterial conjunctivitis in pediatric patients. Pediatr Infect Dis J. 2010;29(3):222-226.
28. Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM; AzaSite Clinical Study Group. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol. 2008;145(6):959-965.
29. Igami TZ, Holzchuh R, Osaki TH, Santo RM, Kara-Jose N, Hida RY. Oral azithromycin for treatment of posterior blepharitis. Cornea. 2011;30 (10):1145-1149.
30. Veldman P, Colby K. Current evidence for topical azithromycin 1%ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness. Int Ophthalmol Clin. 2011;51(4):43-52.
31. Singh R, Joseph A, Umapathy T, Tint NL, Dua HS. Impression cytology of the ocular surface. Br J Ophthalmol. 2005;89(12):1655-1659.
32. McKelvie P. Ocular surface impression cytology. Adv Anat Pathol. 2003;10(6):328-337.
33. Nolan GR, Hirst LW, Bancroft BJ. The cytomorphology of ocular surface squamous neoplasia by using impression cytology. Cancer. 2001;93(1):60-67.
34. Thiel MA, Bossart W, Bernauer W. Improved impression cytology techniques for the immunopathological diagnosis of superficial viral infections. Br J Ophthalmol. 1997;81(11):984-988.
35. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008;27(1):64-69.
36. Sheppard JD Jr, Singh R, McClellan AJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea. 2013;32(10): 1297-1304. doi:10.1097/ICO.0b013e318299549c.
37. Mohammed I, Abedin A, Tsintzas K, et al. Increased expression of hepcidin and toll-like receptors 8 and 10 in viral keratitis. Cornea. 2011;30 (8):899-904.
38. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258(11):7155-7160.
39. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998; 16:137-161.
40. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996; 15(6):605-614.
41. Yoshino K, Garg R, Monroy D, Ji Z, Pflugfelder SC. Production and secretion of transforming growth factor beta (TGF-beta) by the human lacrimal gland. Curr Eye Res. 1996;15(6):615-624.
42. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24: 99-146.
43. Bongiovanni L, Müller EJ, Della Salda L. Survivin in skin pathologies. Exp Dermatol. 2011;20 (6):457-463.
44. Xiao YQ, Malcolm K, Worthen GS, et al. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem. 2002;277(17):14884-14893.
45. Incorvaia C, Frati F, Puccinelli P, et al. Effects of sublingual immunotherapy on allergic inflammation. Inflamm Allergy Drug Targets. 2008; 7(3):167-172.
46. Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988;140(9):3026-3032.
47. Tiemessen MM, Kunzmann S, Schmidt-Weber CB, et al. Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response. Int Immunol. 2003;15(12):1495-1504.